Following fast-track designations for Imugene, landmark Phase 2 data from Orca Bio and with growing traction in HLA-matching strategies, the Chief Executive Officer at OneChain Immunotherapies is right to suggest that the allogeneic products are ‘poised for prime time.’

Unite with 80+ experts at the 7th Annual Allogeneic Cell Therapies Summit, to address critical challenges in optimizing complex gene engineering, upscaling cell production and navigating the regulatory landscape, to bring these transformative off-the-shelf therapies to market.

Brainstorm with industry experts at Adicet Bio, Takeda, AstraZeneca, Cellectis, Caribou Biosciences and more, to develop effective strategies that demonstrate the potential of off-the-shelf therapies for patients in need.

Event link here.